Hepatic FXR may act as a tumor suppressor in hepatocellular carcinoma (HCC) and is also associated with liver injury and cholestasis. Therefore, avoiding hepatic FXR antagonism is critical when ...

In this study, the authors first used an AlphaScreen assay to identify a series of tryptophan-based cyclic peptide compounds with FXR-antagonistic activity, specifically those modified with a ...

By that time the cholestasis was more pronounced, and there was slight focal or disseminated fatty degeneration. Neither hepatocellular necrosis nor evidence of reactive inflammation was found (Fig.

hepatocellular carcinoma cancer immunobiology immunogenetics immunotherapy ... For instance, in Patient 1, T5 and T10 appeared soft and white, while other lesions looked yellow with cholestasis; in ...

Research indicates that after 5 years of UDCA therapy, the incidence of liver decompensation in PBC patients is between 3.81% and 4.31%, while the rate of hepatocellular carcinoma development ...

For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and ...

The FDA has issued a complete response letter for rivoceranib plus camrelizumab as a first-line treatment for unresectable ...

A research team led by Prof. Sun Cheng from the University of Science and Technology of China (USTC), in collaboration with ...

Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, accounts for about 75–85% of all liver cancer ...